drugset / Trial / NCT00003840
DTGM Fusion Protein in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia
Treatment
Summary
RATIONALE: DTGM fusion protein may be able to locate cancer cells and stop them from growing. PURPOSE: Phase I/II trial to study the effectiveness of DTGM fusion protein in treating patients who have recurrent or refractory acute myeloid leukemia.
Timeline
- Start
- 2000-10
- Primary completion
- 2002-09
- Completion
- 2005-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DTGM fusion protein | Protein / enzyme biologic | — | Intravenous |